Skip to main content
Article
Trends in Pharmaceutical Expenditures: The Impact on Drug Benefit Design
Meyers Primary Care Institute Publications and Presentations
  • Joanne LaFleur
  • Leslie S. Fish, University of Massachusetts Medical School
  • Diana I. Brixner
UMMS Affiliation
Meyers Primary Care Institute
Date
5-1-2008
Document Type
Article
Medical Subject Headings
Drug Industry; Pharmaceutical Preparations; Drug Costs
Abstract
Annual national spending for pharmaceutical agents was increasing at a rapid pace during the late 1990s and early part of the 21st century, outpacing increases in spending on hospital care and on physician services, which had dominated the industry in the 1970s. In the past few years, however, this trend has shifted, resulting in a lower growth rate in 2005. The reasons for these trends of increases and subsequent declines are explained in this article, including the slower pace of increase in generics and the increasing role of biologic agents in the rate of pharmaceutical price inflation. The sharp increases in drug spending led to changes in prescription drug benefit designs that have not been fully tested. The recent decline creates an opportunity for health plans to evaluate the value of current and new strategies and implement value-based benefit designs in accordance with the shifting focus in healthcare toward value-based patient care. [AHDB, 2008;1(4):29-34.]
Comments

Citation: LaFleur J, Fish L, Brixner D. Trends in Pharmaceutical Expenditures: The Impact on Drug Benefit Design. American Health & Drug Benefits 2008;1(4):29-34.

Citation Information
Joanne LaFleur, Leslie S. Fish and Diana I. Brixner. "Trends in Pharmaceutical Expenditures: The Impact on Drug Benefit Design" Vol. 1 Iss. 4 (2008)
Available at: http://works.bepress.com/leslie_fish/8/